Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationHumansPhenylurea CompoundsPyridinesStomach NeoplasmsQuality of Life
Health-related quality-of-life outcomes with regorafenib in advanced gastric and esophagogastric junction cancer: results from the INTEGRATE trials.
Andrew J Martin, Yu Yang Soon, Katrin Marie Sjoquist, Nick Pavlakis, David Goldstein, Kohei Shitara, John R Simes
Published: 202510.1007/s10120-025-01670-2
Abstract
BACKGROUND: The INTEGRATE trials evaluated regorafenib in advanced gastric and esophagogastric junction cancer (AGOC), a poor prognosis population. In INTEGRATE 1 (I1, phase 2), regorafenib improved progression-free survival (PFS) without a clear exc…
Preview only. Read the full abstract at the source